Icotrokinra vs Atacicept: Comparing Two Newly FDA-Approved Immunomodulatory Peptides

Icotrokinra and atacicept are two of 2026's most closely watched immunomodulatory peptide approvals, but they sit at opposite ends of peptide drug design: one is a small oral macrocycle, the other a large injectable fusion protein, and both reached FDA approval within four months of each other for entirely different indications. Icotrokinra (ICOTYDE) is a first-in-class oral macrocyclic peptide antagonist of the interleukin-23 receptor approved for plaque psoriasis, while atacicept (Trutakna) is a TACI-Fc fusion protein that dually neutralizes BAFF and APRIL, approved for IgA nephropathy. Researchers studying peptide-based immunomodulation increasingly compare the two not because they compete for the same indication, but because they illustrate how differently "peptide therapeutic" can be engineered to hit an immune target.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: Icotrokinra and atacicept are both FDA-approved immunomodulatory peptides from 2026, but they are not interchangeable or comparable for the same condition — icotrokinra is an oral IL-23 receptor antagonist for plaque psoriasis, while atacicept is an injectable BAFF/APRIL-inhibiting fusion protein for IgA nephropathy, and researchers select between peptide modalities like these based on target pathway rather than head-to-head efficacy.

TL;DR:

• Icotrokinra is a small oral macrocyclic peptide (IL-23R antagonist); atacicept is a large subcutaneous TACI-Fc fusion protein (dual BAFF/APRIL inhibitor).
• Icotrokinra: FDA approved March 18, 2026, for moderate-to-severe plaque psoriasis, based on the ICONIC Phase 3 program (~2,500 patients).
• Atacicept: FDA accelerated approval July 7, 2026, for IgA nephropathy, based on interim Phase 3 ORIGIN 3 data.
• Both compounds represent a broader 2026 trend of peptide- and protein-based agents displacing small-molecule and biologic incumbents in autoimmune and inflammatory disease research.
• Neither compound is 503A-eligible for compounding; both are FDA-approved branded products only.

Icotrokinra: Mechanism and Evidence Base

Icotrokinra (also known as JNJ-2113 or JNJ-77242113) is a macrocyclic peptide built from natural and noncanonical amino acids, cyclized via a disulfide bond. That structure is what makes it unusual among peptide therapeutics: it is orally bioavailable, avoiding the injection requirement that limits most peptide drugs. Mechanistically, icotrokinra binds the interleukin-23 receptor (IL-23R) with high selectivity, blocking IL-23 signaling without disrupting IL-12, which shares the IL-12Rβ1 subunit. Since IL-23 sits upstream of the IL-17 axis that drives psoriatic plaque formation, blocking the receptor suppresses downstream IL-17A, IL-17F, IL-22, and TNF-α production.

The clinical evidence base comes from the ICONIC Phase 3 program, which enrolled approximately 2,500 patients across four randomized, double-blind, placebo-controlled trials (PMID 40278440). In the pivotal ICONIC-LEAD trial (NCT06934226), 65% of patients achieved IGA 0/1 (clear or almost clear skin) and 50% achieved PASI 90 at week 16. Head-to-head data from ICONIC-ADVANCE 1 & 2 showed superiority over deucravacitinib, an oral TYK2 inhibitor. A separate ulcerative colitis study also met its primary endpoint, suggesting the IL-23R antagonism mechanism has research relevance beyond dermatology. The FDA approved icotrokinra on March 18, 2026, for adults and adolescents 12 and older weighing at least 40 kg. Full mechanism and trial detail is cataloged on the icotrokinra library profile.

Atacicept: Mechanism and Evidence Base

Atacicept (atacicept-vymj, marketed as Trutakna) works through an entirely different structural class. It is a 313-amino-acid TACI-Fc fusion protein — the extracellular BAFF/APRIL-binding domain of the TACI receptor fused to a modified human IgG1 Fc region, with a dimeric mass of roughly 73.4 kDa. Rather than blocking a receptor on target tissue the way icotrokinra does, atacicept acts as a decoy receptor circulating in serum, simultaneously neutralizing two upstream cytokines: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Both cytokines drive B-cell survival and maturation, and in IgA nephropathy specifically, they promote production of pathogenic galactose-deficient IgA1 that deposits in the kidney's mesangium.

Atacicept's evidence base builds across three trial phases. Phase 2 JANUS (NCT02808429, PMID 35967104) established initial dose-finding in patients with persistent proteinuria despite standard-of-care therapy. Phase 2b ORIGIN (PMID 38552841, n=116) showed urine protein-to-creatinine ratio (UPCR) reductions of 31% from baseline in combined atacicept arms versus 8% with placebo at week 24, alongside a 60% reduction in galactose-deficient IgA1 versus placebo. The pivotal Phase 3 ORIGIN 3 trial (PMID 41196369, NCT04716231), published in NEJM in February 2026, reported a prespecified interim analysis of 203 patients showing once-weekly subcutaneous atacicept 150 mg reduced UPCR by 45.7% from baseline versus 6.8% with placebo at week 36 — a 41.8 percentage-point between-group difference (P<0.001). Based on that interim data, the FDA granted Vera Therapeutics accelerated approval for Trutakna on July 7, 2026, making atacicept the first approved therapy to dually inhibit BAFF and APRIL. Continued approval depends on confirmatory verification of long-term kidney function preservation. Full profile data is available on the atacicept library page.

Side-by-Side Comparison

Differential Research Applications

Because icotrokinra and atacicept target different diseases through unrelated pathways, researchers do not choose between them in the way they might choose between two GLP-1 agonists or two GHRH analogues. Instead, the pairing is instructive for a different reason: it shows two solutions to the same underlying problem in peptide drug design — how to make a peptide-scale therapeutic durable and target-selective enough for chronic autoimmune or inflammatory dosing. Icotrokinra's macrocyclic, noncanonical-amino-acid scaffold solves that problem by achieving oral bioavailability, a genuine rarity for a peptide that hits an intracellular-adjacent receptor target. Atacicept solves it by fusing a natural receptor-binding domain to an Fc region, borrowing the pharmacokinetic stability of an antibody scaffold to extend half-life and enable weekly subcutaneous dosing of a fundamentally protein-based decoy receptor.

For researchers tracking the broader immunomodulatory pipeline — including which additional peptide- and protein-based candidates are advancing through FDA review — the clinical trial tracker aggregates trial status across compounds by phase and indication, which is useful context for benchmarking where icotrokinra's ulcerative colitis expansion work and atacicept's confirmatory kidney-function trial currently stand.

Regulatory and Compounding Status

Both compounds are FDA-approved branded products and neither is eligible for 503A compounding pharmacy preparation. Icotrokinra is approved as ICOTYDE, an oral once-daily tablet, for plaque psoriasis in patients 12 years and older weighing at least 40 kg; WADA is expected to evaluate icotrokinra given its immunomodulatory mechanism, though no prohibited-list determination has been finalized. Atacicept is approved as Trutakna under accelerated approval, meaning the FDA's authorization is contingent on the ongoing Phase 3 ORIGIN 3 trial confirming durable kidney function benefit; if confirmatory data does not support the surrogate endpoint (proteinuria reduction), approval status could be revisited. Both are prescription-only, provider-administered or provider-prescribed therapeutics, not research compounds available through compounding channels.

Cited Studies

• PMID 40278440 — "Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents." (New England Journal of Medicine, 2026). DOI: https://doi.org/10.1056/NEJMoa2504187
• PMID 41196369 — "A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy." (New England Journal of Medicine, 2026). DOI: https://doi.org/10.1056/NEJMoa2510198
• PMID 38552841 — Phase 2b ORIGIN trial of atacicept in IgA nephropathy.
• PMID 35967104 — Phase 2 JANUS dose-finding trial of atacicept.

Frequently asked questions

Q: Is icotrokinra the same type of drug as atacicept?

A: No. Icotrokinra is a small, orally bioavailable macrocyclic peptide that antagonizes the IL-23 receptor, while atacicept is a much larger injectable TACI-Fc fusion protein that neutralizes BAFF and APRIL. They belong to different structural classes and treat different diseases.

Q: What is icotrokinra approved for?

A: The FDA approved icotrokinra (ICOTYDE) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents 12 years and older weighing at least 40 kg, based on the ICONIC Phase 3 trial program.

Q: What is atacicept approved for?

A: Atacicept (Trutakna) received FDA accelerated approval on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression, based on interim Phase 3 ORIGIN 3 data.

Q: Can icotrokinra or atacicept be obtained through compounding pharmacies?

A: No. Both are FDA-approved branded prescription products (ICOTYDE and Trutakna respectively) and are not eligible for 503A compounding.

Q: Why are researchers comparing two peptides that treat different diseases?

A: Icotrokinra and atacicept are frequently discussed together because both reached FDA approval in 2026 as examples of peptide- and protein-based immunomodulation displacing older small-molecule and biologic approaches, even though their specific disease targets do not overlap.

See also:

• Icotrokinra vs Thymosin Alpha-1: Comparing Two Immunomodulatory Research Peptides — another icotrokinra comparison focused on innate versus adaptive immune modulation.
• Rusfertide Hepcidin Mimetic: Phase 3 VERIFY Trial Data and FDA Priority Review Status — a look at another 2026 late-stage peptide nearing commercial approval.
• Best Peptides for Immune Function Research: 7 Compounds Ranked by Evidence — broader context on immunomodulatory peptide research.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.